Both mastocytosis and breast cancer are lump-based in clinical manifestations and have similarities in pathogenesis. Is mastocytosis easy to turn into breast cancer? The relationship between mastocytosis and breast cancer is a complex issue, and the relationship between these two diseases should be understood from the following aspects. First of all, it must be clear that these two diseases are qualitatively different from each other. Mastocytosis is a benign, non-tumor disease. Breast cancer, on the other hand, is a malignant tumor of the breast. The treatment and prognosis of these two diseases are very different. Although mastocytosis and breast cancer are two different diseases, they are both caused by endocrine disorders and are both associated with high estrogen levels. In terms of epidemiology, both are related to psychological factors, marriage, childbirth and breastfeeding, and the risk factors for the development of mastocytosis are also risk factors for the development of breast cancer, which indicates that there are similarities in pathogenesis. The clinical manifestations of mastocytosis and breast cancer are similar and often misdiagnose each other: mastocytosis and early breast cancer both have lumps as the main clinical manifestation, and breast lumps are the basis for the diagnosis of mastocytosis; most patients with breast cancer also have breast lumps as the symptom, so they often misdiagnose each other in the diagnosis. Especially, about one-fifth of breast cancer patients have atypical clinical manifestations, which increases the factor of misdiagnosis. For example, some breast cancer lumps have clear or relatively clear sides; some breast cancer lumps have good mobility; and some breast cancer lumps are multiple. These symptoms are consistent with the characteristics of mastocytosis, so in clinical practice, breast cancer with atypical clinical manifestations is often misdiagnosed as mastocytosis. According to some statistics, the clinical misdiagnosis rate is about 12-16%. Clinically, the diagnosis of early breast cancer or atypical breast cancer as mastocytosis is the main reason for misdiagnosis of breast cancer. Scholars at home and abroad have long found that breast cancer specimens are often accompanied by cystic breast disease, and the proportion of breast cancer with cystic disease is between 20 and 80%. These indicate that mastocytosis and breast cancer can occur simultaneously. In clinical practice, some patients with mastoproliferative disease do not insist on regular checkups, so that after the appearance of cancer, they still think it is the original hyperplastic disease, thus delaying the treatment. The existence of mastoproliferative disease can conceal the detection of new cancer, so you should go to the hospital for regular breast examination to avoid delaying the treatment. In theory, any cancer is the final result of cellular hyperplasia, which is a qualitative change of cellular hyperplasia on the basis of quantitative change. It goes through the process of mild hyperplasia – high hyperplasia – atypical hyperplasia – cell mutation – cancerous hyperplasia. So in this sense alone, mastoproliferative disease can eventually develop into breast cancer. However, since the development of hyperplasia is not a never-ending process, most hyperplastic cells do not continue to develop after reaching a certain level and stagnate at a certain stage, which is still reversible as long as they do not become cancerous, in fact, only a very small number of mastoproliferative diseases may develop into breast cancer. In the development of breast cancer, most breast cancers come from the ductal epithelium. And patients with atypical hyperplasia are as much as 6-18 times more likely to develop breast cancer than patients with mastopathy without atypical hyperplasia. Atypical hyperplasia is classified into three degrees: mild, moderate and severe, while severe atypical hyperplasia is closely related to breast cancer, so severe atypical hyperplasia is called precancerous lesion of breast cancer. In terms of pathological types, a large amount of foreign information affirms that cystic hyperplasia of the breast is more prone to severe atypical hyperplasia, which is considered as precancerous hyperplasia of breast cancer. In this way, we can divide mastoproliferative diseases into two categories: general hyperplasia and precancerous hyperplasia, and only severe atypical hyperplasia and some cystic hyperplasia can be considered precancerous lesions of breast cancer. Among the various types of breast hyperplasia, the proportion of precancerous hyperplasia is less than 20%, while severe atypical hyperplasia accounts for about 3%. Moreover, cystic hyperplasia is common in women in China, so if you suffer from mastopathy, you can still achieve good prevention as long as you treat it actively.